The double-blind trial included 1,767 patients in 16 countries. When compared to formoterol fumarate dihydrate — the conventional treatment of the disease — Flutiform did not significantly reduce the annual rate of worsening condition in patients with moderate to severe COPD.
“Whilst this result is disappointing, Flutiform continues to grow strongly based on the approved asthma indication, which continues to underpin our expectations for future growth of the product,” said James Ward-Lilley, CEO of Vectura.
Flutiform reported $103.3 million in net sales for the past six months ending in June.
More articles on supply chain:
The rise of the unbranded drug ad: 5 things to know
FDA fast tracks experimental drug to treat Parkinson’s
Roche’s Zika test earns FDA emergency use authorization
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
